Article Text

PDF
FRI0191 Incidence of disease worsening in inflammatory arthritis patients on long-term innovator infliximab therapy
  1. AM Marrache1,
  2. E Psaradellis2,
  3. J Vaillancourt2,
  4. E Rampakakis2,
  5. F Nantel1
  1. 1Medical Affairs, Janssen Inc., Toronto
  2. 2JSS Medical Research, Montreal, Canada

Abstract

Background A recent randomized controlled study in a single country reported rates of disease worsening over a one-year follow-up period for innovator infliximab (REMICADE®, IFX) and a comparator in various diseases including AS and RA. After a mean duration of treatment of 6.7 years of innovator IFX, rates for disease worsening post-one year follow-up were 39.5% in AS and 36.7% in RA1. Other such data reporting disease worsening rates are rare.

Objectives Using data from a longitudinal database, the objective was to determine the incidence of disease worsening in AS and RA patients on long-term therapy with innovator IFX. PsA patients were not included in this study due to low numbers (n=49).

Methods BioTRAC is an ongoing, prospective registry of inflammatory arthritis patients initiating treatment with infliximab, golimumab or ustekinumab that has been ongoing since 2002 in Canada. We included AS and RA patients who had been on innovator IFX therapy for at least two, four or six years. Disease worsening endpoint was defined as follows: for AS patients; an increase in ASDAS ≥1.1 from baseline and a minimum score of 2.1. For RA patients; an increase in DAS28 ≥1.2 from baseline and a minimum score of 3.2.

Results This analysis included a total of 196 AS and 425 RA patients. Among AS patients, 36.1% were female, 90.8% were bio-naïve at IFX initiation and 50% were on concomitant NSAID(s) at the 2-year index. The mean (SD) ASDAS score was 2.17 (1.05). As for the RA patients, 75% were female, 88.5% were bio-naïve, and 93% were on concomitant DMARD(s) while 35% were on corticosteroids at the 2-year index. The mean (SD) DAS28 ESR and DAS 28 CRP were 3.37 (1.40) and 3.00 (1.24), respectively.

As shown in table 1, the incidence of disease worsening in AS and RA patients on stable IFX for 2–6 years was low and varied from 2.7% to 11.5% at the subsequent 12 and 24 months visit.

Table 1.

Incidence of disease worsening in AS and RA patients at the 2, 4, and 6-year index

Conclusions In this prospective longitudinal cohort, patients on long-term innovator IFX therapy show low rates of disease worsening of 2.7% to 11.5% at 1 and 2 years in AS and RA. Additional studies may elucidate the true rate of and reasons for disease worsening in rheumatologic populations.

References

  1. Goll et al. Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway. Arthritis Rheum 2016;68(S10). Abstract 19L.

References

Disclosure of Interest A. M. Marrache Employee of: Janssen Inc., E. Psaradellis Employee of: JSS Medical Research, J. Vaillancourt Employee of: JSS Medical Research, E. Rampakakis Employee of: JSS Medical Research, F. Nantel Employee of: Janssen Inc.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.